Article category
EHL research
Progress of ADSTEM, KDSTEM, RASTEM, patents and EHL awards.
EHL research
ADSTEM Research Timeline: Adipose-Derived Stem Cell Innovation for Atopic Dermatitis
Explore the development journey of ADSTEM, EHL BIO's autologous adipose-derived mesenchymal stem cell therapy, from early clinical trials to the current Phase 3 status.
12 Oct 2026
EHL research
In-Depth Results of ADSTEM Phase 2 Clinical Trial: Innovative Stem Cell Therapy for Atopic Dermatitis
Summary of the successful ADSTEM Phase 2 clinical trial results, showcasing the significant efficacy of autologous adipose-derived stem cells in reducing Atopic Dermatitis severity.
12 Oct 2026
EHL research
ADSTEM Achievement: Advancing to Phase 3 Clinical Trials for Atopic Dermatitis Treatment
EHL BIO receives IND approval for ADSTEM Phase 3 clinical trials, a self-adipose-derived stem cell therapy, to confirm efficacy and safety in treating moderate-to-severe atopic dermatitis.
12 Oct 2026
EHL research
KDSTEM: Innovative Urine-Derived Stem Cells for Chronic Kidney Disease Recovery
Discover KDSTEM, the world's first urine-derived stem cell innovation by EHL BIO, approved for clinical trials as a new restorative alternative for chronic kidney disease patients.
12 Oct 2026
EHL research
RASTEM: Stem Cell Innovation for Rheumatoid Arthritis Research
EHL BIO develops RASTEM, an autologous adipose-derived mesenchymal stem cell therapy, as a new alternative for Rheumatoid Arthritis management through immune modulation.
12 Oct 2026
EHL research
PDSTEM: Advancing Stem Cell Research for Parkinson's Disease Recovery
Discover PDSTEM, an innovative autologous adipose-derived mesenchymal stem cell therapy under development by EHL BIO, targeting neuro-regeneration for Parkinson's disease.
12 Oct 2026
EHL research
Keycell-IM: Innovative Immune Cell Research for Recovery and Health Improvement
Explore Keycell-IM by EHL BIO, an autologous immune cell therapy derived from the patient's blood, focused on managing abnormal cells and improving quality of life under Korean GMP standards.
12 Oct 2026
EHL research
Research and Innovation in Adipose-Derived Stem Cell Exosomes
Explore the advancements in Adipose-Derived Stem Cell (ADSC) Exosomes, a nano-innovation for tissue regeneration and anti-inflammation currently under medical development.
12 Oct 2026
EHL research
What is IND? The Importance of Investigational New Drug Approvals in Regenerative Medicine
Learn about IND (Investigational New Drug), a critical regulatory step ensuring the safety and quality of EHL BIO's cell therapy products before clinical application based on EHL team assessments.
12 Oct 2026
EHL research
Understanding Clinical Trial Phases 1–3: Safety Standards and Innovation at EHL BIO
Explore the essential stages of clinical trials from Phase 1 to 3, ensuring safety and efficacy of cell therapies under EHL BIO's international standards in South Korea.
12 Oct 2026
EHL research
Patented Compounds for Rheumatoid Arthritis: Advancing to New Standards in Restoration
EHL BIO has secured a patent for compounds targeting rheumatoid arthritis, marking a significant milestone in cell therapy to balance the immune system and restore joint health.
12 Oct 2026
EHL research
EHL BIO's Selection for National Regenerative Medicine Technology Development Projects
EHL BIO has been selected by the South Korean government for ministry-level research projects to develop innovative stem cell therapies for chronic kidney disease and atopic dermatitis.
12 Oct 2026
EHL research
Research and Publications: Regenerative Medicine Innovations by EHL BIO
Discover EHL BIO's research milestones, from international journal publications to patented cell culture technologies developed under strict GMP standards.
12 Oct 2026
EHL research
Global Research Synergy: EHL BIO and Leading University Hospital Partnerships
EHL BIO advances regenerative medicine through MOU signings and clinical research collaborations with top-tier university hospitals in Korea, driving safe and effective cell therapy innovations.
12 Oct 2026
EHL research
The Future of Regenerative Medicine with EHL BIO: Cell Innovation for Sustainable Quality of Life
EHL BIO advances the future of regenerative medicine through GMP-standard stem cell and immune cell technologies, focusing on recovery from age-related decline.
12 Oct 2026
EHL research
ADSTEM and KDSTEM: EHL BIO's research progress
A summary of EHL BIO's main programmes, from skin and kidney to joints.
3 Sept 2026
Frequently asked questions
What stage is ADSTEM at?
ADSTEM completed Phase 2 in 2023 and had a Phase 3 IND submitted in 2024.
Not sure whether this applies to your case?
Send your questions and initial information through the form. Our team will help prepare your case for an individual assessment with EHL Cell Clinic in Korea.
Consult EHL Thailand